Milestones
Week 4
96.9 kg
-3.1% from baseline
Week 12
91.7 kg
-8.3% from baseline
Week 24
85.5 kg
-14.5% from baseline
Week 36
82.1 kg
-17.9% from baseline
Week 48
80.1 kg
-19.9% from baseline
Week 60
79.1 kg
-20.9% from baseline
Week 72
78.4 kg
-21.6% from baseline
What this tool helps you do
This calculator estimates a trial-average timeline to a goal weight using embedded weekly weight-loss curves for tirzepatide, semaglutide, and retatrutide.
If you are already on treatment, it first estimates a virtual starting weight so the curve can continue from your current point.
How it works
Method
Use clinical trial weight-loss curves
Each medication maps to a weekly percent-loss curve. Tirzepatide and semaglutide use 72-week horizons, while retatrutide uses a 48-week horizon.
Retatrutide supports two dose buckets, including a high-dose curve that reaches about 24.2% at week 48.
Method
Project beyond the trial only if needed
If the goal is not reached within the trial horizon, the calculator extends the projection using the slope observed in the final weeks.
Any such estimate is clearly marked as extrapolated because real-world weight loss often slows or plateaus.
Formula or method
Projected weight = Baseline weight × (1 + Percent change from baseline)
If already on treatment: Estimated baseline = Current weight ÷ (1 + Percent loss at current week)
Extrapolated week uses the recent slope from the end of the trial curve
Example
On the tirzepatide curve, a 100 kg baseline reaches about 78.4 kg by week 72.
On the semaglutide curve, a 100 kg baseline reaches about 84.6 kg by week 72.
Assumptions and limitations
This is a population-average planning tool, not a personal prediction engine.
Compounded medication, lower adherence, dose changes, or plateaus can shift timelines materially.
Source review
Reviewed
Glone Source Review Team
Public-source fact checking for GLP-1 content
See the medical review policy and reviewer profile here.
FAQ
No. It only shows how the embedded trial-average curve behaves under those assumptions.
Because it reconstructs an estimated baseline weight so the curve continues from your current stage instead of restarting from week one.
Because the projected goal lies beyond the published trial horizon, so the tool extends the curve using recent slope rather than direct trial data.
Sources
method
Glone planning tool methodology
How Glone documents interpolation, label-based branching, modeled curves, schedule generation, and plotted exposure estimates.
clinical
SURMOUNT-5
Public tirzepatide vs semaglutide trial reference used for the core planning curves.
clinical
Retatrutide phase 2
Public phase 2 retatrutide weight-loss reference used for dose-bucket planning curves.
Important notes
These tools provide educational estimates and do not replace individualized medical advice.
Population-average curves and label rules do not capture every person, formulation, or clinical scenario.
Learn more about how Glone handles content quality in the editorial policy.
Related tools
Related guides
Dosing
Mounjaro Dose Titration: Step-by-Step Schedule
A simple step-by-step view of the Mounjaro titration schedule and what changes as your weekly dose increases.
Comparisons
Wegovy vs Ozempic: Key Differences Explained
A plain-language comparison of weekly semaglutide options, including routine fit and key differences.
Education
How Do GLP-1 Medications Work? A Simple Guide
A simple explainer on how GLP-1 medications affect appetite, digestion, and routine tracking over time.
Glone
Track the real routine behind the numbers
Glone turns weekly injections, symptoms, meals, water, and weight into a routine history you can actually review over time.